Compare AdaptHealth Corp (AHCO) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AdaptHealth Corp vs Gilead Sciences, Inc. — how do they compare? AdaptHealth Corp trades at $10.03 (market cap $1.38B), while Gilead Sciences, Inc. trades at $135.27 (market cap $169.30B). The key difference: Gilead Sciences, Inc. is far larger — about 122.7× AdaptHealth Corp's market cap, and Gilead Sciences, Inc. pays a 2.41% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | GILD | |
|---|---|---|
Market Cap | $1.38B | $169.30B |
Sector | Health | Health |
52-Week High | $13.38 | $155.80 |
52-Week Low | $8.68 | $108.22 |
Enterprise Value | $3.33B | $183.83B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
Gilead Sciences (GILD) trades at $136.36, up 3.88% today and 25.2% over the past year, showing strong momentum. The stock exhibits bullish technical signals with support at $128 and resistance at $136. Fundamentally, GILD maintains robust profitability with a 30.99% net margin and has beaten earnings estimates for three consecutive quarters. Recent FDA and EC approvals for Trodelvy's expanded use in metastatic triple-negative breast cancer provide significant growth catalysts.
GILD presents a compelling investment case with strong analyst support (65.5% buy ratings) and a $156.14 consensus price target offering 14.5% upside. Key risks include generic competition for dolutegravir and execution challenges in oncology growth. The company's solid cash flow generation and expanding product portfolio support continued shareholder value creation despite recent negative net cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AdaptHealth Corp
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
